Clinical profile of early-onset Parkinson’s disease
Objective: Describe motor and non-motor symptoms, complications and treatment in patients with early-onset Parkinson's disease (EOPD) Background: PD usually affecting people over age 60, clinically…Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease
Objective: We sought to determine whether fecal bile acids (BAs) could affect levodopa response assessed by levodopa challenge test (LCT) in patients with Parkinson’s disease…Levodopa response is an inadequate and often biased correlate of STN-DBS outcomes
Objective: To investigate the reliability of the relationship between levodopa response and subthalamic nucleus (STN) DBS outcomes in Parkinson disease (PD). Background: Levodopa response (LR)…The bypassing and embedded PEG J
Objective: Our aim is to highlight the improvement on quality of life of using a duodenal levodopa infusion. In addition, we want to emphasize the continuing…If Oral Levodopa is not Possible, Keep Calm and Breathe Deeply
Objective: Include inhaled levodopa as a therapeutic option in those patients who, due to post-surgical problems, cannot use oral treatments. Background: The development of motor…Wearable sensors and AI in Parkinson’s disease – How continuous symptom and treatment response monitoring can enable better clinical decision making – Interim results from an observational study
Objective: To investigate how continuous objective information on motor symptoms and treatment response combined with subjective patient reported insights can be used to optimize Parkinson’s…NLX-112 has favorable safety and tolerability and displays efficacy against levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD)
Objective: To assess the safety, tolerability and preliminary efficacy of NLX-112 (a.k.a. befiradol) in patients with moderate to severe LID in PD: a randomized, double-blind,…What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)
Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…The diagnosis value of dopaminergic responsiveness of Parkinson’s disease： a systematic review and meta-analysis
Objective: aimed to confirm the diagnostic value/accuracy of levodopa and/or apomorphine challenge test in parkinsonian syndromes (PDS) to assess their value in the diagnosis of…Integrated analysis of phase 3 trials of foslevodopa/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation.
Objective: To characterize reported infusion site infection adverse events (AEs) and their clinical management in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 57
- Next Page »